Your browser doesn't support javascript.
loading
Pharmacological treatment of depression in people with a primary brain tumour.
Beevers, Zachary; Hussain, Sana; Boele, Florien W; Rooney, Alasdair G.
Afiliación
  • Beevers Z; School of Medicine, University of Leeds, Leeds, UK.
  • Hussain S; School of Medicine, University of Leeds, Leeds, UK.
  • Boele FW; Leeds Institute of Health Sciences and Leeds Institute of Cancer and Pathology, University of Leeds and Leeds Cancer Centre, Leeds, UK.
  • Rooney AG; Robert Fergusson Unit, Royal Edinburgh Hospital, Edinburgh, UK.
Cochrane Database Syst Rev ; 7: CD006932, 2020 07 17.
Article en En | MEDLINE | ID: mdl-32678464
BACKGROUND: This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear. OBJECTIVES: To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour. SEARCH METHODS: We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019). SELECTION CRITERIA: We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour. DATA COLLECTION AND ANALYSIS: No studies met the inclusion criteria. MAIN RESULTS: We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour. AUTHORS' CONCLUSIONS: We identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Depresión / Antidepresivos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Depresión / Antidepresivos Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Cochrane Database Syst Rev Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article